Cited 0 times in
Risk factors predicting Severe Asthma exacerbations in adult asthmatics: A real-world clinical evidence
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ban, GY | - |
dc.contributor.author | Kim, SC | - |
dc.contributor.author | Lee, HY | - |
dc.contributor.author | Ye, YM | - |
dc.contributor.author | Shin, YS | - |
dc.contributor.author | Park, HS | - |
dc.date.accessioned | 2022-12-26T00:39:21Z | - |
dc.date.available | 2022-12-26T00:39:21Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 2092-7355 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/23558 | - |
dc.description.abstract | Purpose: Minimizing the future risk of asthma exacerbation (AE) is one of the main goals of asthma management. We investigated prognostic factors for risk of severe AE (SAE) in a real-world clinical setting. Methods: This is an observational study evaluating subjects who were diagnosed with asthma and treated with anti-asthmatic medications from January 1995 to June 2018. Risk factors for SAE were analyzed in 2 treatment periods (during the initial 2 years and the following 3-10 years of treatment) using the big data of electronic medical records. Results: In this study, 5, 058 adult asthmatics were enrolled; 1, 335 (28.64%) experienced ≥ 1 SAE during the initial 2 years of treatment. Female sex, higher peripheral eosinophil/basophil counts, and lower levels of forced expiratory volume in 1 second (FEV1; %) were factors predicting the risk of SAEs (P < 0.001 for all). Higher serum total immunoglobulin E levels increased the risk of SAEs among the patients having ≤ 2 SAEs (P = 0.025). Patients with more frequent SAEs during the initial 2 years of treatment had significantly higher risks of SAEs during the following years of treatment (P < 0.001, for all) (patients with ≥ 4 SAEs, odds ratio [OR], 29.147; those with 3 SAEs, OR, 14.819; those with 2 SAEs, OR, 9.867; those with 1 SAE, OR, 5.116), had higher maintenance doses of systemic steroids, and showed more gradual decline in FEV1 (%) and FEV1/forced vital capacity levels maintained during the following years of treatment (P < 0.001 for all). Conclusions: Asthmatics having risk factors for SAEs (female sex, higher peripheral eosinophil/basophil counts, and lower FEV1) should be strictly monitored to prevent future risk and improve clinical outcomes. | - |
dc.language.iso | en | - |
dc.title | Risk factors predicting Severe Asthma exacerbations in adult asthmatics: A real-world clinical evidence | - |
dc.type | Article | - |
dc.identifier.pmid | 33733637 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984950/ | - |
dc.subject.keyword | Adults | - |
dc.subject.keyword | Asthma | - |
dc.subject.keyword | Basophils | - |
dc.subject.keyword | Eosinophils | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | IgE | - |
dc.subject.keyword | Respiratory function tests | - |
dc.subject.keyword | Risk factors | - |
dc.subject.keyword | Steroids | - |
dc.contributor.affiliatedAuthor | Ye, YM | - |
dc.contributor.affiliatedAuthor | Shin, YS | - |
dc.contributor.affiliatedAuthor | Park, HS | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.4168/AAIR.2021.13.3.420 | - |
dc.citation.title | Allergy, asthma & immunology research | - |
dc.citation.volume | 13 | - |
dc.citation.number | 3 | - |
dc.citation.date | 2021 | - |
dc.citation.startPage | 420 | - |
dc.citation.endPage | 434 | - |
dc.identifier.bibliographicCitation | Allergy, asthma & immunology research, 13(3). : 420-434, 2021 | - |
dc.identifier.eissn | 2092-7363 | - |
dc.relation.journalid | J020927355 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.